Speaker
Description
The integration of oncolytic virotherapy and chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising strategy for enhancing anti-tumor efficacy in the treatment of solid tumors. Oncolytic viruses selectively infect and destroy cancer cells while simultaneously modifying the tumor microenvironment, potentially improving CAR-T cell infiltration and activity. Understanding the complex interactions among tumor cells, oncolytic viruses, and CAR-T cells is essential for designing effective treatment protocols.
In this work, we develop and analyze a mathematical model describing the dynamics of tumor progression under combined oncolytic virus and CAR-T cell therapy. The model incorporates key biological mechanisms, including viral infection and replication, tumor cell lysis, and CAR-T cell expansion and persistence. To optimize therapeutic outcomes while minimizing treatment burden and adverse effects, we formulate a switched optimal control problem in which treatment interventions are administered according to time-dependent switching strategies.
